ORIGINAL ARTICLE



Check for updates

The impact of liver transplantation on health-related quality of life in (acute) intoxication-type inborn errors of metabolism

Benedetta Greco^{1,2} | Stefania Caviglia² | Diego Martinelli¹ Teresa Grimaldi Capitello | Daniela Liccardo | Francesca De Nictolis | Andrea Pietrobattista | Martina Huemer | Simone Piga | Giorgia Olivieri | Gionata Spagnoletti⁶ | Marco Spada⁶ | Carlo Dionisi-Vici¹

²Unit of Clinical Psychology, Bambino Gesù Children's Hospital IRCCS, Rome,

³Division of Hepatology, Gastroenterology and Nutrition, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

⁴Division of Metabolism, Children's Research Center and University Children's Hospital Zurich, Zurich, Switzerland

⁵Unit of Clinical Epidemiology, Medical Direction, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

⁶Unit of Hepato-Biliary-Pancreatic Surgery, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

Correspondence

Carlo Dionisi-Vici, Division of Metabolism Diseases, Bambino Gesù Children's Hospital IRCCS, Piazza Sant'Onofrio 4, Rome 00165, Italy.

Email: carlo.dionisivici@opbg.net

Funding information

La vita è un dono ONLUS; Ministero della Salute

Communicating Editor: Sven Garbade

Abstract

Organic acidurias (OAs), urea-cycle disorders (UCDs), and maple syrup urine disease (MSUD) belong to the category of intoxication-type inborn errors of metabolism (IT-IEM). Liver transplantation (LTx) is increasingly utilized in IT-IEM. However, its impact has been mainly focused on clinical outcome measures and rarely on health-related quality of life (HRQoL). Aim of the study was to investigate the impact of LTx on HrQoL in IT-IEMs. This single center prospective study involved 32 patients (15 OA, 11 UCD, 6 MSUD; median age at LTx 3.0 years, range 0.8-26.0). HRQoL was assessed pre/post transplantation by PedsQL-General Module 4.0 and by MetabQoL 1.0, a specifically designed tool for IT-IEM. PedsQL highlighted significant post-LTx improvements in total and physical functioning in both patients' and parents' scores. According to age at transplantation (≤ 3 vs. > 3 years), younger patients showed higher post-LTx scores on Physical (p = 0.03), Social (p < 0.001), and Total (p = 0.007) functioning. MetabQoL confirmed significant post-LTx changes in Total and Physical functioning in both patients and parents scores $(p \le 0.009)$. Differently from PedsQL, MetabQoL Mental (patients p = 0.013, parents p = 0.03) and Social scores (patients p = 0.02, parents p = 0.012) were significantly higher post-LTx. Significant improvements (p = 0.001-0.04) were also detected both in self- and proxy-reports for almost all MetabQoL subscales. This study shows the importance of assessing the impact of transplantation on HrQoL, a meaningful outcome reflecting patients' wellbeing. LTx is associated with significant improvements of HrQol in both self- and parentreports. The comparison between PedsQL-GM and MetabQoL highlighted that MetabQoL demonstrated higher sensitivity in the assessment of diseasespecific domains than the generic PedsQL tool.

Abbreviations: HrQoL, health-related quality of life; IT-IEM, intoxication-type inborn errors of metabolism; LTx, liver transplantation; MSUD, maple syrup urine disease; OA, organic acidurias; UCD, urea-cycle disorders.

¹Division of Metabolic Diseases, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

15732656, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jimd.12648 by Cochrane Germany, Wiley Online Library on [09/07/2033]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons Licenson

KEYWORDS

health-related quality of life, intoxication-type inborn errors of metabolism, maple syrup urine disease, MetabQoL, organic acidurias, PedsQL, urea-cycle disorders

1 | INTRODUCTION

Organic acidurias (OAs), urea-cycle disorders (UCDs), and maple syrup urine disease (MSUD) belong to the category of intoxication-type inborn errors of metabolism (IT-IEM). The main treatment for these diseases is a lifelong protein-restricted diet combined with the supplementation of special amino acid mixtures, which substantially limits the consumption of natural foods. 1-3 Moreover, in OAs and UCDs chronic administration of pharmacotherapy is also needed. 1,2 Despite adequate treatment adherence, patients are at permanent risk of acute events of metabolic decompensation causing potentially irreversible neurological damage, or even death. Moreover, neurodevelopmental impairment and behavioral problems may also occur due to the progression of chronic central nervous system alterations.4 Regular highly specialized medical follow-up visits are essential for the long-term management and prolonged or repeated hospitalizations may often become necessary in phases of treatment readjustment or deterioration. Taken together, all these factors considerably contribute to the high disease burden faced by patients and their families and may consequently result in an impaired health-related quality of life (HrQoL). HrQoL is a multidimensional construct, which includes the impact of disease on patients' physical, psychological, and social functioning.^{5,6} Studies investigating HrQol in IT-IEM are still scarce and often have methodological limitations, such as the small sample size, the use of generic assessment tools, or the use of questionnaire based exclusively on parent or on selfreports.^{7,8} To overcome some of these limitations, a recent analysis involving a large sample of pediatric IT-IEM patients from six international reference metabolic centers was conducted. The study showed considerably impaired HrQoL and identified the strict diet regimen as a risk factor for lower scores in HrQoL questionnaires.⁷ Research to ameliorate treatment and care in the field of IT-IEM has resulted in improved long-term outcome and patients' survival. Therefore, the improvement of the HrQoL of patients and families becomes an increasingly fundamental focus of comprehensive healthcare.^{8,9} Beside dietary treatment and pharmacotherapy, liver transplantation (LTx) is increasingly used in IT-IEM^{10,11} to reduce the risk of metabolic decompensation, prevent long-term complications, diminish disease burden, and improve patient's HrQoL.¹² However, although LTx in

IT-IEM has become a more frequent therapeutical option, ^{10,13} to date little is known about its impact on HRQoL at follow-up. Improvements in HrQoL post transplantation have been reported, however outcomes were mainly assessed by generic tools, ¹⁴ qualitative analysis and as physician's descriptions ^{13,15} or assessed by unvalidated questionnaires. ¹² Moreover, the limited data from quantitative studies often originate from heterogeneous patient cohorts with different diseases, in which IT-IEMs are under-represented, ^{16–19} highlighting the need of more structured evaluations.

Aim of our study was to quantify the impact of LTx in HrQoL in a cohort of 32 IT-IEM patients treated by LTx at the Bambino Gesù Children's Hospital, including both parents' and patients' perspectives. To obtain a broader view of the changes induced by transplantation, HrQoL was assessed with the generic PedsQL⁶ and with the disease specific MetabQoL,²⁰ a tool recently developed to evaluate HrQoL in IT-IEM patients, and so far never utilized for transplant-related evaluations.

2 | METHODS

2.1 | Sample and procedure

Thirty-two study participants undergoing LTx were recruited from 36 IT-IEM patients listed for LTx regularly followed or referred to the Division of Metabolism of Bambino Gesù Children's Hospital in Rome (Italy). Eligible participants for the study were parents/caregivers of LTx candidates with IT-IEM and patients from age 7 years. To form the study group, parents and patients were enrolled from 2011 to 2021. One patient with propionic acidemia and severe cardiac disease died at the age of 17 years, 3 months after LTx.

The study was approved by the Bambino Gesù Children's Hospital ethical committee (2937_OPBG-2022).

Data were collected by the psychologist of the patient's healthcare team, after explaining to patients and their families the purpose of the study and the content of the questionnaires used. To reduce hospital admissions, pre- and post-LTx evaluations were carried out during regular medical follow-up visits. Assessment was completed before the inclusion in the transplant list and repeated every 6 months until LTx. Post-LTx assessment were completed at least 2 months post-LTx and repeated

every 6 months. To the aim of our study, we considered at pre-LTx assessment the closest evaluation to LTx and at post-LTx the latest available follow-up data.

2.2 **Outcome measures**

HRQoL was assessed pre- and post-LTx by the generic PedsQL-GM4.0⁶ and by the IT-IEM-specific MetabQoL 1.0.²⁰

2.3 PedsQL

Parents completed the PedsQL-GM-parent version, a validated instrument, available in Italian, widely used to detect the perception of the impact of disease and its treatment on patient's HrQoL, assessing functioning in Physical, Emotional, Social, and School/Work domains.⁶ Scores range from 0 to 100, with higher scores indicating a better HrQoL.⁶ There are several versions of the tool, covering a wide age range from the first months of life to adulthood. To ensure the homogeneity and comparability of the results within the sample used, only the domains common to each age were considered (Physical, Emotional, and Social). Patients completed a self-report version of the PedsQL that replicates the parent-report version, with sentences adjustments to reduce the complexity and adapt the questionnaire to the respondent age.

2.4 MetabQoL

MetabQoL is a newly developed IT-IEM-specific tool, designed to assess HrQoL.8,20 It evaluates the impact of IT-IEM on the patient's life both from his point of view and from parents' perspective. Different versions are available to adapt to the patient's age and type of self or parent-report. Patients completed a self-report version of the MetabQoL that replicates the parent-report version, with sentences adjustments to reduce the complexity and adapt the questionnaire to the respondent age. Outcome data can be summarized to obtain a HrQoL total score and, similarly to PedsQL, the best HrQoL was indicated by values of 100, worst by 0. In the MetabQoL version created for patients older than 7 years, item scores can be also aggregated to scale scores: Physical, Mental (corresponding to PedsQL Emotional scale), and Social. Further information can be obtained through 7 subscales: Diet, Drugs, Hospitalization, Living with the disease (belonging to Physical domain), Emotions about the disease (belonging to Mental Domain), Social relations, Stigma (belonging to Social Domain), and an additional subscale, not included in the total score, assessing disease severity during the last

SIEM WILEY 3 12 month. For the present study, the questionnaire was

STATISTICAL ANALYSIS

vised by a metabolic physician of the center.

All statistical analyses were performed using STATA, Statistical Software: Release 13 (StataCorp LP, College Station, TX). The statistical significance was set at p < 0.05. The Shapiro-Wilk test was used to assess the normality of the data. Categorical variables were summarized by absolute frequencies and percentages, and continuous variables by median and interquartile range (IQR). To determine statistical differences between pre-LTx and post-LTx for PedsQL and MetabQoL, Wilkoxon signed rank test was used. A Kruskal-Wallis test was used to determine the significance of differences between groups. Mann-Whitney test was used to compare patients according to the two age groups. Pearson correlation coefficients were calculated in a subgroup of 10 parent-child dyads to analyze self and parent-report relations.

RESULTS

This single-center study involved parents of 32 LTx recipients with IT-IEM, between 2011 and 2021 (Table 1): 15 OAs, 11 UCDs, and 6 MSUD. Three out of 6 patients with methylmalonic aciduria were treated by combined liver and kidney transplantation. Median age at transplantation was 3 years (range, 8 months to 26 years).

Assessment was completed pre-LTx (time from pretest to LTx: median 3 months, range: 0-11 months) and post-LTx (time from LTx to post-test; median 2.5 years, range: 0.2-10 years).

Ten out of 32 patients (6 OA, 3 UCD, 1 MSUD; median age at LTx: 16.5 years, range: 9-26 years) (Table S1) were able to independently complete the selfreport version of the questionnaires administered to their parents (parent-child dyads). Assessment was completed pre-LTx (time from pre-test to LTx: median 4 months, range: 0-11 months) and post-LTx (time from LTx to post-test; median 1.5 years, range: 0.2-9 years).

4.1 **PedsOL**

HrQoL of children reported by 4.1.1 parents

A Wilcoxon signed rank test showed significant post-LTx improvement of Total, Physical, and Emotional

15732665, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jimd.12648 by Cochrane Germany, Wiley Online Library on [09/07/2023]. See the Terms

of use; OA articles are governed by the applicable Creative Commons License

TABLE 1 Participants characteristics (N = 32).

	Median	Range
Age at LTx, years	3	0.8-26
Months between pre-LTx assessment and LTx	3	0–11
Years between LTx and post-LTx assessment	2.5	0.2-10
Sex	N	%
Male	19	59
Female	13	41
Diagnosis	N	%
Organic acidurias (OA)	15	47
Age at LTx, years	4	0.8-26
Propionic aciduria (PA)	9	28
Methylmalonic aciduria (MMA)	6	19
Urea cycle disorders (UCD)	11	34
Age at LTx, years	4	1–11
Carbamoyl phosphate synthetase I deficiency (CPS)	3	9
Ornithine transcarbamylase deficiency (OTC)	2	6
Argininosuccinic aciduria (ASA)	6	19
Maple syrup urine disease (MSUD)	6	19
Age at LTx, years	2	0.9–16

functioning Scales compared with pre-LTx. Post-LTx improvement of Social Scales was not statistically significant (Table 2).

To detect an at-risk status for impaired HrQoL, one standard deviation below the population mean was defined as meaningful cut-off point score. Total scores pre-LTx showed that 41% of patients were in the "at-risk status for impaired HrQoL" compared with only 19% at post-LTx assessment. Regarding the specific domains, Physical functioning was the most impaired pre-LTx subscale and showed the highest post-LTx improvement (44% vs. 13% of patients below the cut-off). Also in Emotional and Social functioning subscales the percentage of patients below the cut-off decreased from pre to post-LTx (respectively, 25% vs. 16%; 34% vs. 28%).

The subgroup analyses of the three disease groups (OA, UCD, MSUD), showed significant post-LTx improvement of Total Score in all subgroups. Physical functioning improved significantly in OA and UCD but not in MSUD (Table 2). No statistically significant difference between the three disease groups were detected by Kruskal–Wallis test in both pre- (Total score p=0.319; Physical functioning p=0.177; Emotional functioning p=0.601; Social functioning p=0.302) and post-LTx

TABLE 2 Pre- and post-LTx PedsQL and MetabQoL parent-report scores.

	PedsQL Total score	ore			Physical functioning	ming		Emotional functioning	tioning		Social functioning	ing	MetabQoL	Total score		
Patients N	Median (IQR) Pre		Post	p value	Median (IQR) Pre	Post	p value	Median (IQR) Pre	Post	p value	Median (IQR) Pre	Post	p value	Median (IQR) Pre	Post	p value
Total sample 32	72.0 (52.8	8, 80.0)	32 72.0 (52.8, 80.0) 81.0 (70.5, 90.3)	<0.001	68.0 (40.1, 81.8)	84 (72.0, 97.0)	<0.001	72.5 (63.8, 85.6)	85.0 (75.0, 90.0)	0.02	70.0 (50.0, 95.0)	80.0 (58.8, 96.3)	0.24	52.3 (40.0, 60.8)	52.3 (40.0, 60.8) 70.5 (66.3, 79.4)	<0.001
15	57.0 (50.0	0, 73.5) 7	15 57.0 (50.0, 73.5) 76.0 (66.5, 84.5)	0.004	0.004 62.5 (29.0, 73.5)	78.0 (69.0, 89.0)	0.001	75.0 (57.5, 86.3)	75.0 (57.5, 86.3) 80.0 (75.0, 90.0) 0.109	0.109	65.0 (44.5, 87.5)	65.0 (44.5, 87.5) 75.0 (52.5, 87.5) 0.264	0.264	49.0 (37.5, 61.5)	49.0 (37.5, 61.5) 67.5 (60.0, 74.5)	<0.001
11	78.0 (52.5	5, 82.0) 8	11 78.0 (52.5, 82.0) 84.0 (70.5, 90.0)	0.011	0.011 75.0 (48.5, 87.5)	95.0 (73.5, 98.5)	9000	79.0 (70.0, 85.0)	79.0 (70.0, 85.0) 85.0 (82.5, 90.0) 0.283	0.283	75.0 (62.5, 92.5)	75.0 (62.5, 92.5) 80.0 (62.5, 92.5) 0.943	0.943	52.5 (45.0, 58.8)	52.5 (45.0, 58.8) 75.0 (70.5, 87.8)	0.006
MSUD 6	74.5 (72.	5, 76.5) 8	74.5 (72.5, 76.5) 89.5 (78.0, 93.5)	0.03	72.0 (66.8, 91.5)	94.0 (84.3, 96.3)	0.281	68.0 (65.5, 84.8)	85.0 (68.8, 97.5)	0.400	92.5 (58.8, 100)	95.0 (86.3, 100)	0.684	52.5 (48.4, 63.8)	73.8 (69.3, 77.5)	0.03
rs at Ltx 17	75.0 (55.0	0,83.0) 8	≤3 years at Ltx 17 75.0 (55.0, 83.0) 87.0 (80.0, 92.0)	<0.001	69.0 (34.0, 87.5)	94.0 (78.0, 100)	0.002	79.0 (65.0, 87.5)	85.0 (80.0, 90.0)	0.003	85.0 (65.0, 100)	90.0 (80.0, 100)	0.285	52.5 (37.5, 60.0)	70.0 (62.5, 77.5)	<0.001
rs at Ltx 15	57.0 (48.0	0, 76.5) 7	>3 years at Ltx 15 57.0 (48.0, 76.5) 71.0 (59.0, 80.0)	0.007	62.5 (44.0, 75.0)	75 (59.5, 87.5)	0.002	70.0 (65.0, 85.0)	75.0 (55.0, 90.0)	0.833	55.0 (42.5, 72.5)	55.0 (42.5, 72.5) 60.0 (45.0, 72.5) 0.639	0.639	49.0 (45.0, 64.0)	49.0 (45.0, 64.0) 72.0 (69.5, 85.8)	0.001

Abbreviations: IQR, interquartile range; MSUD, maple syrup urine disease; OA, organic acidurias; UCD, urea cycle disorders.

ssiem

(Total score p=0.281; Physical functioning p=0.426; Emotional functioning p=0.744; Social functioning p=0.172) comparison.

According to the median-split method, we divided the patients' sample into two groups based on the median age at transplantation (≤3 and >3 years). As reported in Table 2, Total and Physical functioning scores were significantly improved post-LTx in both age categories, while Emotional functioning was significantly improved by LTx only in younger patients. No significant improvements were recorded in Social functioning scale in both age categories.

Between group comparisons using Mann–Whitney test showed, at pre-LTx significantly lower Social functioning scores in patients >3 years versus patients \leq 3 years (55.0 vs. 85.0, p=0.012). No other significant differences were recorded in Total score (57.0 vs. 75.0, p=0.104), Physical functioning (62.5 vs. 69.0, p=0.364), and Emotional functioning (70.0 vs. 79.0, p=0.895) subscales. At post-LTx evaluation, the highest scores were recorded in younger patients (\leq 3 years): Total score (87.0 vs. 71.0, p=0.007), Physical (94.0 vs. 75.0, p=0.03), and Social functioning (90.0 vs. 60.0, p<0.001), with no significant difference in Emotional functioning scale (85.0 vs. 75.0, p=0.123).

4.1.2 | Self-reported HrQoL of children versus parent-report

Positive changes post-LTx in Total and Physical functioning were recorded for both patient- and parent-report, with no significant improvements in Emotional and Social functioning (Table 3).

According to meaningful PedsQL cut-off point scores, ²¹ 60% of patient reports showed an at-risk status for impaired HrQoL in the Total score at the pre-LTx evaluation, a percentage reduced to 20% at post-LTx. Regarding the specific domains, Physical functioning was the most impaired pre-LTx subscale with 80% of patients below the cut-off versus only 30% at post-LTx. Also in Emotional and Social functioning subscales the percentage of patients below the cut-off decreased from pre to post-LTx (respectively, 20% vs. 10%; 40% vs. 20%).

As for the reports of their parents, Total scores pre-LTx showed that 61% of patients were in the "at-risk status for impaired HrQoL" compared with 30% at post-LTx assessment. Also in Physical functioning the percentage of patients below the cut-off decreased from 60% at pre-LTx to 30% at post-LTx. Differently from what reported by their children, parents showed fewer positive changes al post-LTx in other subscales: Emotional functioning slightly worsened (30% vs. 40%) and Social domain remained below cut-off in 60% of patients as at pre-LTx.

Pre- and post-LTx PedsQL and MetabQOL self and parent-report scores of 10 parent-child dyads. TABLE 3

	Self-report								Parent report							
	PedsQL				MetabQoL				PedsQL				MetabQoL			
HrQoL	Total score Median HrQoL (IQR)	Fotal score Physical Median Median (IQR)	Emotional Median (IQR)	Social Median (IQR)	Total score I Median I (IQR) (Physical Median (IQR)	Mental (Median)	Social Median (IQR)	Total score Physical Median Median (IQR) (IQR)		Emotional Median (IQR)	Social Median IQR)	Total score Physical Median (IQR) (IQR)		Mental S Median M	Social Median (IQR)
Pre	67.3 (60.8, 71.5)	.3 62.5 70.0 70.0 49.0 (60.8, 71.5) (50.0, 70.5) (66.3, 78.8) (50.0, 82.5) (39.8, 64.5)	70.0 (66.3, 78.8)	70.0 (50.0, 82.5)		50.0 (42.0, 65.3)	56.0 (39.6, 61.4)	44.5 (36.8, 66.6)	54.8 (47.5, 70.8)	56.3 (42.5, 71.3)	70.0 (62.5, 75.0)	50.0 (41.3, 68.8)	50.5 (47.0, 69.8)	58.0 (51.0, 79.0)	50.0 56.0 44.5 54.8 56.3 70.0 50.0 50.5 58.0 54.0 57.0 (42.0, 65.3) (39.6, 61.4) (36.8, 66.6) (47.5, 70.8) (42.5, 71.3) (62.5, 75.0) (41.3, 68.8) (470, 69.8) (31.0, 79.0) (460, 65.9) (36.8, 61.0)	57.0 (36.8, 61.0)
Post	83.3 (72.3, 86.8)	.3 84.3 80.0 80.0 80.5 (72.3, 86.8) (75.8, 92.4) (80.0, 83.8) (70.0, 88.8) (77.5, 82.0)	80.0 (80.0, 83.8)	80.0 (70.0, 88.8)		82.0 (76.0, 86.5)	75.0 (75.0, 89.8)	78.5 (59.8, 87.1)	70.0 (59.3, 75.3)	75.0 75.3) (55.5, 83.3)	72.5 (48.8, 87.5)	52.5 (42.5, 68.8)	72.0 (69.5, 82.5)	81.0 (74.5, 89.1)	820 75.0 75.0 78.5 70.0 75.0 72.5 52.5 72.0 81.0 71.0 66.0 (76.0, 86.5) (75.0, 89.8) (59.8, 87.1) (59.3, 75.3) (55.5, 83.3) (48.8, 87.5) (42.5, 68.8) (69.5, 82.5) (74.5, 89.1) (62.5, 82.0) (510, 77.6)	66.0 (51.0, 77.6)
<i>p</i> value 0.05	0.05	0.02	0.152	0.312	0.002	0.009	0.013	0.02	0.02	9000	1.000	0.490	0.009	600.0	0.03	0.012

As regards parent–child agreement, at pre-LTx evaluation the Pearson correlation coefficient showed a statistically significant strong relationship between patients and parents reports in Physical functioning (r=0.681, p=0.030). No significant patient–parents reports correlations were detected in Total score (r=0.540, p=0.107), Emotional functioning (r=0.609, p=0.061), and Social functioning (r=0.206, p=0.568) scales. At post-LTx, a strong correlation was observed in Total score (r=0.804, p=0.005), Physical (r=0.792, p=0.006), and Emotional functioning (r=0.821, p=0.004). No significant correlation was detected in Social functioning scale (r=0.387, p=0.270).

4.2 | MetabQoL

4.2.1 | HrQoL of children reported by parents

The MetabQoL Total score significantly improved after LTx (Table 2). The analysis of Total scores within the three disease sub-groups highlighted a better post-LTx HrQoL in each sub-group (Table 2). No statistically significant difference between the three sub-groups (OA, UCD, MSUD) were detected by Kruskal Wallis test in both pre- (Total score p=0.772) and post-LTx (Total score p=0.099) comparison The analysis of patients' sample in the two groups according to median age at transplantation, showed a significantly improved Total score in both age groups (Table 2). Between group comparisons using Mann–Whitney test showed no significant differences between the two groups (≤ 3 years and > 3 years) in both pre- (p=0.570) and post-LTx (p=0.374) Total scores.

4.2.2 | Self-reported HrQoL of children versus parent-report

MetabQoL highlighted significantly improved post-LTx scores, for both self- and parent-report, in all scales (Table 3).

Moreover, patients and their parents reported significantly positive changes (*p* range 0.001–0.037) in most subscales: Diet, Living with a disease, Emotion about the disease, Stigma, and Disease severity (Figure 1). Although showing a positive post-LTx trend, Social relation in patient- and Drugs subscales in parent-reports did not reach statistical significance. No significant changes in the Hospitalization subscale both by patient- and parent-reports were recorded.


As regards parent-child agreement, at pre-LTx evaluation, no significant correlations were detected by Pearson correlation coefficients in Total score (r=0.256, p=0.476), Physical (r=0.189, p=0.601), Mental (r=0.145, p=0.690), and Social (r=0.461, p=0.180) scales. At post-LTx, a strong correlation was observed in Mental scale (r=0.870, p=0.001), while no significant correlations were detected in Total score (r=0.442, p=0.201), Physical (r=0.014, p=0.969), and Social (r=0.427, p=0.218) scales. Compared with PedsQL, MetabQoL raw scores showed smallest differences between patients and their parents' reports.

5 | DISCUSSION

Improving HrQoL is one of the major aims of liver transplantation in pediatric patients with IT-IEM. However, to date, little is known about the impact of transplantation on these patients' HrQoL at follow-up. Our study aimed to provide an in depth understanding on this topic by evaluating the impact of LTx on HrQoL, including both the generic PedsQL and the IT-IEM specific Metab-QoL tools. The design of this work did not include the evaluation of post-LTx long-term complication.

In our study, all baseline (i.e., pre-LTx) PedsQL scores were lower than those reported by Bösch et al.⁷ in a cohort of non-transplanted IT-IEM patients, and lowest when compared with chronically and acutely ill children affected by other diseases than IT-IEM.⁶ Similarly, also the baseline evaluation by MetabQoL indicated lower scores in both patient and parent assessments.²⁰ Compared with pre-LTx, post-LTx assessment showed significant HrQoL improvements with both tools, regardless of individual disease categories. Our data are consistent with the improved post-LTx HrQoL in a cohort of IT-IEM patients qualitatively evaluated by an ad-hoc designed questionnaire.¹²

The ideal timing of liver transplantation is a main and debated issue in pediatric IT-IEM patients. Recent data reported that in Europe 6% of OA and UCD patients were transplanted before 1 year of age, while in the United States this percentage was to 33%. ¹² In general, existing studies have shown that early liver transplantation improves long term neurological and developmental outcome, prevents morbidity from recurrent metabolic decompensation and relieves patients from restrictive diets. ^{13,15,22} In our sample, both age-related groups reported a higher post transplantation HrQoL but patients transplanted before the age of 3 years showed more improvements than those transplanted later. Thus, early transplantation in IT-IEM patients should be considered as the preferable option. ^{23,24}






FIGURE 1 MetabQoL subscales assessment pre-LTx, white bars, and post-LTx, gray bars, in patient (top panel) and in parent (bottom panel) reports. Diet, Drugs, Hospitalization, and Living with the disease subscales belong to Physical domain; Emotions about the disease subscale belongs to Mental domain; Social relations and Stigma subscales belong to Social domain.

Regarding the specific HrQoL domains, Physical functioning scores assessed by PedsQL showed the greatest impairment pre-LTx and the most improvement post-LTx in both patients- and parent-reports. The impact of transplantation on Emotional and Social domains was also positive with differences between parents' and patients' reports and between earlier and later

transplanted individuals. A possible explanation could be that positive changes in the Physical domain are easier recognized and quantifiable in shorter post-operative intervals than Social and Mental functioning. ^{20,25} Another variable could be the specifics of HrQoL evaluation in a pediatric cohort. At the time of transplantation, the majority of patients were too young to answer a

questionnaire, so their HrQoL was assessed by parents' report. It is known that parents' proxy scorings are influenced by factors related to parents' own HrQoL. 26,27 This impact might be even stronger in IT-IEMs, in which the high complexity of diseases and treatment combined with an often unpredictable disease courses may have a significant negative impact on parents' experience and HrQoL. 28 Since disease-specific tools show higher responsiveness to HrQoL changes over time and are more sensitive, 4,29 for a better understanding of these aspects, we utilized in our study the MetabQoL, specifically designed for IT-IEM category. 20

Assessment by MetabQoL confirmed a significant post-LTx improvement in the Physical Domain. Unlike PedsQL-GM, MetabQoL allowed to evaluate this dimension on IT-IEM patients more specifically by referring to characteristic symptoms and treatments. The MetabQoL considers the restrictive diet and the taste of special lowprotein food, the tightly scheduled intake of food and drugs, need of tube feeding, frequent nausea/vomiting, limited exercise tolerance, and the risk of life-threatening metabolic decompensations that may cause constant fear of crises and potential neurological sequelae. 25,30-32 From our patients' perspective, liver transplantation had a significant impact on their HrOoL mainly through a liberalized dietary regimen, reduced pharmacotherapy burden, less physical complaints, reduced risk of metabolic crises and tube feeding. Parents confirmed the point of view of their children, reporting positive changes in HrQoL as reported in other studies. 11,14,33,34 Interestingly no significant changes were reported in the "hospitalization" dimension, both by patients and parents. This likely reflects the need of post-LTx hospitalization (also in ICU) and, after discharge, of frequent scheduled evaluations and procedures, especially in the early post-operative period. Hospital stays reduce leisure times and interfere with everyday life, blood sampling and other necessary invasive procedures (e.g., liver biopsy) can be very stressful and frightening.8 Moreover, fear of liver rejection and the threat of re-transplantation may intensify the emotional burden. Taken together, these issues highlight that a tailored psychological support is necessary to help patients and their parents to develop coping strategies to manage stress and anxiety better. 35,36

Regarding Emotional and Social functioning subscales, no significant changes were recorded both by patient and parents PedsQL reports. In particular, from the parents' perspective the majority of patients remained within the at-risk status for impaired HrQoL also after transplantation. In contrast, the MetabQoL Mental dimension which evaluates patient's emotions about their disease (e.g., concern for the future), showed significant improvements post-LTx in both self- and parent-reports.

Similarly, also the Social dimension which analyses the impact of the disease on relationship with peers and family members and on social stigma showed significant improvements. Nevertheless, post-LTx scores on the stigma dimension were still the lowest when compared with other subscales both by parents and patients' reports. Experiences of social exclusion and the difficulty to explain the clinical complexity of a rare disease in a simple and comprehensive way remains a major concern from patients' and parents' perspective.²⁵

The partial agreement between parents and patients' reports in our study is not surprising. Previous studies^{26,27,37,38} showed that in families with a child with a chronic disease, parent-child agreement is higher for visible characteristics evaluated by the Physical domain than for non-visible characteristics evaluated with Emotional or Social subscales. Furthermore, when patients grow older they could experience more difficulties to verbalize their feelings, or choose not to share their concerns and personal burdens with their caregiver.³⁹ Our results are consistent with these findings, and the better parentchild agreement—with the smallest differences in raw scores—by MetabOoL, could be explained by the greater relevance and sensitivity of this tool which utilizes information collected by focus group of parents and patients with IT-IEMs, interviewed as content experts.²⁵

6 | CONCLUSION

Aim of the study was to investigate the impact of LTx on HrQoL in IT-IEMs. Results showed that patients' HrQoL significantly improved post-LTx, in both self- and parent-reports.

The combined use of two tools—the generic PedsQL and the IT-IEM-specific MetabQoL—allowed to perform a complete assessment of patients' HrQoL and highlighted that MetabQoL added specific disease-related content. Our results support the importance to consider HrQoL evaluation as a meaningful LTx outcome and encourage to include this aspect into transplant decision making, as a parameter and indication for transplantation itself, as recently recommended by the European Association for the Study of the Liver. 40

Lastly, although the present study clearly demonstrates a positive impact of LTx in improving HrQoL, families should be informed that after LTx patients may be not eligible for novel gene-related therapies which are fast arriving for those conditions.

ACKNOWLEDGMENTS

Alice Donati, Elena Procopio (Metabolic and Muscular Unit, A. Meyer Children's Hospital, Florence, Italy),

JIMD SISEM _WILEY _____9

Simona Fecarotta, Giancarlo Parenti (Department of Translational Medical Science, Section of Pediatrics, Metabolic Diseases Unit, Federico II University of Naples, Naples, Italy), Albina Tummolo, Rita Fischetto (Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, Bari, Italy), Cettina Meli (Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy), Valentina Rovelli, Sabrina Paci, Alessio Peretti, Alessandra Corato (ASST Santi Paolo e Carlo e ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) for referring their patients to the OPBG Center for liver transplantation.

All members of the multidisciplinary Transplant Team of the Bambino Gesù Children's Hospital IRCCS. The Division of Metabolism is affiliated member of the European Reference Network for hereditary Metabolic Disorders (MetabERN) and partner of the Unified European Registry for Inherited Metabolic Disorders (UIMD) and of the European Registry and network for Intoxication type Metabolic Diseases (E-IMD). The Unit of Hepato-biliary-pancreatic surgery is affiliated member of the European Reference Network Transplant Child; the Division of Hepatology, gastroenterology and nutrition is affiliated member of the European Reference Network Rare Liver. The study was approved by the Bambino Gesù Children's Hospital Ethical Committee (2937 OPBG2022).

FUNDING INFORMATION

This work was supported by funding from the not forprofit sector (La Vita è un Dono ONLUS) and by the Italian Ministry of Health with "Current Research funds."

CONFLICT OF INTEREST STATEMENT

All authors state that they have no competing interests to declare.

ORCID

Marco Spada https://orcid.org/0000-0003-0796-6847 Carlo Dionisi-Vici https://orcid.org/0000-0002-0007-3379

REFERENCES

- 1. Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. *J Inherit Metab Dis.* 2021;44: 566-592.
- Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. *J Inherit Metab Dis*. 2019;42:1192-1230.
- 3. Frazier DM, Allgeier C, Homer C, et al. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. *Mol Genet Metab.* 2014;112:210-217.

- Walterfang M, Bonnot O, Mocellin R, Velakoulis D. The neuropsychiatry of inborn errors of metabolism. *J Inherit Metab Dis*. 2013;36:687-702.
- Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? *Pharmacoeconomics*. 2016:34:645-649.
- Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. *Med Care*. 2001; 39:800-812.
- 7. Bösch F, Landolt MA, Baumgartner MR, et al. Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: analysis of an international data set. *J Inherit Metab Dis.* 2021;44:215-225.
- Zeltner NA, Huemer M, Baumgartner MR, Landolt MA. Quality of life, psychological adjustment, and adaptive functioning of patients with intoxication-type inborn errors of metabolism a systematic review. *Orphanet J Rare Dis.* 2014; 9:159.
- Kruszka P, Regier D. Inborn errors of metabolism: from preconception to adulthood. Am Fam Physician. 2019;99: 25-32.
- 10. McKiernan PJ, Ganoza A, Squires JE, et al. Evolving trends in liver transplant for metabolic liver disease in the United States. *Liver Transpl.* 2019;25:911-921.
- 11. Oishi K, Arnon R, Wasserstein MP, Diaz GA. Liver transplantation for pediatric inherited metabolic disorders: considerations for indications, complications, and perioperative management. *Pediatr Transplant*. 2016;20:756-769.
- Molema F, Martinelli D, Hörster F, et al. Liver and/or kidney transplantation in amino and organic acid-related inborn errors of metabolism: an overview on European data. *J Inherit* Metab Dis. 2021;44:593-605.
- Elserafy N, Thompson S, Dalkeith T, et al. Liver transplantation in children with inborn errors of metabolism: 30 years experience in NSW, Australia. *JIMD Rep.* 2021;60:88-95.
- Splinter K, Niemi AK, Cox R, et al. Impaired health-related quality of life in children and families affected by methylmalonic acidemia. *J Genet Couns*. 2016;25:936-944.
- 15. Brassier A, Krug P, Lacaille F, et al. Long-term outcome of methylmalonic aciduria after kidney, liver, or combined liver-kidney transplantation: the French experience. *J Inherit Metab Dis.* 2020;43:234-243.
- 16. Alonso EM, Limbers CA, Neighbors K, et al. Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipients. *J Pediatr*. 2010;156:270-276.
- 17. Hager A, Mager D, Robert C, Nicholas D, Gilmour S. Health-related quality of life 10 years after liver transplantation: a longitudinal retrospective review. *Diagnostics (Basel)*. 2021; 11:111.
- Ohnemus D, Neighbors K, Rychlik K, et al. Health-related quality of life and cognitive functioning in pediatric liver transplant recipients. *Liver Transpl.* 2020;26:45-56.
- Taylor RM, Franck LS, Gibson F, Donaldson N, Dhawan A. Study of the factors affecting health-related quality of life in adolescents after liver transplantation. *Am J Transplant*. 2009; 9:1179-1188.
- 20. Zeltner NA, Baumgartner MR, Bondarenko A, et al. Development and psychometric evaluation of the MetabQoL 1.0: a

- quality of life questionnaire for paediatric patients with intoxication-type inborn errors of metabolism. JIMD Rep. 2017; 37:27-35.
- 21. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329-341.
- 22. Perito ER, Rhee S, Roberts JP, Rosenthal P. Pediatric liver transplantation for urea cycle disorders and organic acidemias: united network for organ sharing data for 2002-2012. Liver Transpl. 2014;20:89-99.
- 23. Spada M, Calvo PL, Brunati A, et al. Liver transplantation in severe methylmalonic acidemia: the sooner, the better. J Pediatr. 2015;167:1173.
- 24. Macchiaiolo M, Bartuli A, McKiernan P, Dionisi-Vici C, de Ville de Goyet J. Too late to say it is too early - how to get children with non-cirrhotic metabolic diseases transplanted at the right time? Pediatr Transplant. 2012;16:671-674.
- 25. Zeltner NA, Landolt MA, Baumgartner MR, et al. Living with intoxication-type inborn errors of metabolism: a qualitative analysis of interviews with Paediatric patients and their parents. JIMD Rep. 2017;31:1-9.
- 26. Eiser C, Varni JW. Health-related quality of life and symptom reporting: similarities and differences between children and their parents. Eur J Pediatr. 2013;172:1299-1304.
- 27. Upton P, Lawford J, Eiser C. Parent-child agreement across child health-related quality of life instruments: a review of the literature. Qual Life Res. 2008;17:895-913.
- Cederbaum JA, LeMons C, Rosen M, Ahrens M, Vonachen S, Cederbaum SD. Psychosocial issues and coping strategies in families affected by urea cycle disorders. J Pediatr. 2001;138(1 Suppl):S72-S80.
- 29. Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific qualityof-life instruments. J Clin Epidemiol. 2003;56:52-60.
- 30. Cano A, Resseguier N, Ouattara A, et al. Health status of French young patients with inborn errors of metabolism with lifelong restricted diet. J Pediatr. 2020;220:184-192.
- 31. Eminoglu TF, Soysal SA, Tumer L, Okur I, Hasanoglu A. Quality of life in children treated with restrictive diet for inherited metabolic disease. Pediatr Int. 2013:55:428-433.
- 32. Fabre A, Baumstarck K, Cano A, et al. Assessment of quality of life of the children and parents affected by inborn errors

- of metabolism with restricted diet: preliminary results of a cross-sectional study. Health Qual Life Outcomes. 2013;11:158.
- 33. Jang JG, Oh SH, Kim YB, et al. Efficacy of living donor liver transplantation in patients with methylmalonic acidemia. Pediatr Gastroenterol Hepatol Nutr. 2021;24:288-294.
- 34. Chu TH, Chien YH, Lin HY, et al. Methylmalonic acidemia/ propionic acidemia - the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups. Orphanet J Rare Dis. 2019;14:73.
- 35. Graven LJ, Grant JS. Coping and health-related quality of life in individuals with heart failure: an integrative review. Heart Lung. 2013;42:183-194.
- 36. Duff AJ. Incorporating psychological approaches into routine paediatric venepuncture. Arch Dis Child. 2003;88:931-937.
- 37. Rajmil L, López AR, López-Aguilà S, Alonso J. Parent-child agreement on health-related quality of life (HROOL): a longitudinal study. Health Qual Life Outcomes. 2013;11:101.
- 38. Taylor RM, Grieve A, Gibson F, Dhawan A, Franck LS. Parental assessment of adolescent quality of life: can it replace selfassessment? Qual Life Res. 2011;20:1715-1720.
- 39. Witt S, Dellenmark-Blom M, Kuckuck S, et al. Parent-childagreement on health-related quality of life and its determinants in patients born with esophageal atresia: a Swedish-German cross-sectional study. Orphanet J Rare Dis. 2021;16:120.
- 40. Cristin DJ, Forman LM, Jackson WE. Beyond survival: targeting health-related quality of life outcomes after liver transplantation. Clin Liver Dis (Hoboken). 2021;17:359-364.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Greco B, Caviglia S, Martinelli D, et al. The impact of liver transplantation on health-related quality of life in (acute) intoxication-type inborn errors of metabolism. J Inherit Metab Dis. 2023;1-10. doi:10. 1002/jimd.12648